Home/ Stocks/ DRMA

Dermata Therapeutics, Inc. Common Stock

DRMA XNAS

$1.55 +0.00 (+0.00%) ▲ 15-min delayed

Open

N/A

High

N/A

Low

N/A

Volume

N/A

Market Cap

$4.45M

About Dermata Therapeutics, Inc. Common Stock

Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology for patients suffering with acne. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 8 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q3 2025	$0	$-1,691,989	$-1.65
Q1 2025	$0	$-2,303,587	$-0.45
FY 2024	$0	$-12,287,461	$-8.03
Q3 2024	$0	$-3,173,156	N/A

Earnings & Analyst Ratings

Next Earnings: Tue, May 12, 2026

Calendar →

TickerDaily Coverage

Why Is Dermata Therapeutics, Inc. Common Stock (DRMA) Stock Up 51.1% Today?

Penny Stocks Marcus Rivera · 4d ago

Dermata Therapeutics (DRMA) stock exploded 51.1% Friday, March 20, jumping from $1.21 to $1.82 on...

View All Coverage →

Get DRMA Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Dermata Therapeutics, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.